VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease (NCT06249165)
VictORION-INCLUSION: Evaluating INClisiran as a soLUtion to Improve LDL-C Management and cloSe Care Gaps in an Inclusive ASCVD and ASCVD Risk Equivalent populatiON
🩺 Plain-English Summary (8th-Grade Level)
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets.
Who can join: Review the eligibility criteria below.
Location: Univ. of Alabama - Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- Univ. of Alabama - Birmingham — Birmingham, Alabama
- Univ. of California - Irvine — Orange, California
- San Francisco General Hospital — San Francisco, California
- Emory University — Atlanta, Georgia
- Wellstar Paulding — Hiram, Georgia
- Rush University — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- JHU - Suburban Hospital — Bethesda, Maryland
- Johns Hopkins — Columbia, Maryland
- Essentia Health — Duluth, Minnesota
- University of Missouri — Columbia, Missouri
- Washington University — St Louis, Missouri
- University of Nebraska — Omaha, Nebraska
- Heart House of NJ — Haddon Heights, New Jersey
- University of North Carolina — Chapel Hill, North Carolina
- Duke University Medical Center — Durham, North Carolina
- Wake Forest University — Winston-Salem, North Carolina
- Temple University — Philadelphia, Pennsylvania
- Medical Univ. of South Carolina — Charleston, South Carolina
- Houston Methodist — Houston, Texas
- Baylor Scott & White - Waco — Waco, Texas
- University of Utah — Salt Lake City, Utah
- Medical College of Wisconsin — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atherosclerotic Cardiovascular Disease
- Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease — Alexander City, Alabama
- A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease — Boston, Massachusetts
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Birmingham, Alabama
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Birmingham, Alabama
- Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE — Memphis, Tennessee
Explore by condition: All Atherosclerotic Cardiovascular Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.